A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism

American Journal of the Medical Sciences

Volumn 352, Issue 1, 2016, Pages 92-106

  Comerota, Anthony J ^a   Ramacciotti, Eduardo ^b  

^a Jobst Vascular Institute   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulants; Hemorrhage; Venous thromboembolism

Indexed keywords

ACTIVATED CARBON; ANDEXANET ALFA; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; HUMAN; LONG TERM CARE; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VENOUS THROMBOEMBOLISM; BLEEDING; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HEMORRHAGE; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 85008695687     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1016/j.amjms.2016.03.018     Document Type: Review

References (75)

1. 1 Heit, J., Cohen, A., Anderson, F.J., Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood, 106, 2005, 267A.
2. 2 Cohen, A.T., Agnelli, G., Anderson, F.A., et al. Venous thromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost 98 (2007), 756–764.
3. 3 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation 133 (2016), 447–454.
4. 4 Barritt, D.W., Jordan, S.C., Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1 (1960), 1309–1312.
5. 5 Weitz, J.I., Low-molecular-weight heparins. N Engl J Med 337 (1997), 688–698.
6. 6 Gould, M.K., Dembitzer, A.D., Doyle, R.L., et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130 (1999), 800–809.
7. 7 Dolovich, L.R., Ginsberg, J.S., Douketis, J.D., et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 160 (2000), 181–188.
8. 8 Levine, M., Gent, M., Hirsh, J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996), 677–681.
9. 9 Koopman, M.M., Prandoni, P., Piovella, F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 (1996), 682–687.
10. 10 Breddin, H.K., Hach-Wunderle, V., Nakov, R., et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 344 (2001), 626–631.
11. 11 Buller, H.R., Davidson, B.L., Decousus, H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003), 1695–1702.
12. 12 Buller, H.R., Davidson, B.L., Decousus, H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004), 867–873.
13. 13 Ageno, W., Gallus, A.S., Wittkowsky, A., et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e44S–e88S.
14. 14 Jackson, S.L., Peterson, G.M., Vial, J.H., et al. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J 31 (2001), 329–336.
15. 15 Witt, D.M., Delate, T., Clark, N.P., et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood 114 (2009), 952–956.
16. 16 Schulman, S., Beyth, R.J., Kearon, C., et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 257S–298S.
17. 17 Eriksson, B.I., Quinlan, D.J., Weitz, J.I., Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48 (2009), 1–22.
18. 18 Frost, C., Nepal, S., Wang, J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76 (2013), 776–786.
19. 19 Kubitza, D., Becka, M., Voith, B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 (2005), 412–421.
20. 20 Ogata, K., Mendell-Harary, J., Tachibana, M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50 (2010), 743–753.
21. 21 Stangier, J., Rathgen, K., Stahle, H., et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64 (2007), 292–303.
22. 22 Savaysa (edoxaban) prescribing information, http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true. Parsippany, NJ, USA: Daiichi Sankyo, Inc.; 2015. Accessed 21.12.15.
23. 23 Hauel, N.H., Nar, H., Priepke, H., et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 45 (2002), 1757–1766.
24. 24 Wienen, W., Stassen, J.M., Priepke, H., et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98 (2007), 155–162.
25. 25 van Ryn, J., Hauel, N., Waldmann, L., Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood, 2007, 110–114.
26. 26 van Ryn, J., Kink-Eiband, M., Hauel, N., et al. Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma [abstract no. 1884]. Blood, 2007, 110–113.
27. 27 Stangier, J., Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47 (2008), 285–295.
28. 28 Stangier, J., Eriksson, B.I., Dahl, O.E., et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45 (2005), 555–563.
29. 29 Pradaxa (dabigatran etexilate capsules) prescribing information, http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Ridgefield, CT, USA: Boehringer Ingelheim; 2015. Accessed 21.12.15.
30. 30 Clemens, A., Haertter, S., Friedman, J., et al. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification. Curr Med Res Opin 28 (2012), 195–201.
31. 31 European Medicines Agency. Pradaxa (dabigatran etexilate capsules) summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf; 2015. Accessed 21.12.15.
32. 32 Shibano, T., Tsuji, N., Kito, F., et al. Effects of DU-176B, a novel direct factor Xa inhibitor, on prothombinase activity and platelet aggregation in vitro [abstract P-T-642]. J Thromb Haemost, 5(suppl 2), 2007 P-T-642-2.
33. 33 European Medicines Agency. Lixiana (edoxaban tablets) summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf; 2015. Accessed 21.12.15.
34. 34 Tersteegen, A., Burkhardt, N., Rivaroxaban–an oral, direct factor Xa inhibitor–binds rapidly to factor Xa (abstract P-W-651). J Thromb Haemost, 5(suppl 2), 2007 P-W-651-1.
35. 35 Graff, J., von, H.N., Misselwitz, F., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 47 (2007), 1398–1407.
36. 36 Kubitza, D., Becka, M., Wensing, G., et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61 (2005), 873–880.
37. 37 Xarelto (rivaroxaban) prescribing information, http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100. Titusville, NJ, USA: Janssen Pharmaceuticals; 2015. Accessed 21.12.15.
38. 38 Mueck, W., Lensing, A.W., Agnelli, G., et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50 (2011), 675–686.
39. 39 Kubitza, D., Becka, M., Roth, A., et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor. J Clin Pharmacol 53 (2013), 249–255.
40. 40 European Medicines Agency. Xarelto (rivaroxaban) summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf; 2013. Accessed 22.12.15.
41. 41 Raghavan, N., Frost, C.E., Yu, Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37 (2009), 74–81.
42. 42 Frost, C., Wang, J., Nepal, S., et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75 (2013), 476–487.
43. 43 Wong, P.C., Crain, E.J., Xin, B., et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6 (2008), 820–829.
44. 44 Eliquis (apixaban) prescribing information, http://packageinserts.bms.com/pi/pi_eliquis.pdf; 2015. Accessed 21.12.15.
45. 45 Barrett, Y.C., Wang, Z., Frost, C., et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104 (2010), 1263–1271.
46. 46 European Medicines Agency. Eliquis (apixaban) summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf; 2015 Accessed 21.12.15.
47. 47 Becattini, C., Vedovati, M.C., Agnelli, G., Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 129 (2012), 392–400.
48. 48 Kearon, C., Akl, E.A., Ornelas, J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
49. 49 Schulman, S., Kearon, C., Kakkar, A.K., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352.
50. 50 Agnelli, G., Buller, H.R., Cohen, A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
51. 51 Bauersachs, R., Berkowitz, S.D., Brenner, B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
52. 52 Buller, H.R., Prins, M.H., Lensin, A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
53. 53 Schulman, S., Kearon, C., Kakkar, A.K., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368 (2013), 709–718.
54. 54 Agnelli, G., Buller, H.R., Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
55. 55 The Hokusai-VTE Investigators, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415.
56. 56 Schulman, S., Kakkar, A.K., Goldhaber, S.Z., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
57. 57 Heidbuchel, H., Verhamme, P., Alings, M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15 (2013), 625–651.
58. 58 Marlu, R., Hodaj, E., Paris, A., et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 108 (2012), 217–224.
59. 59 Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124 (2011), 1573–1579.
60. 60 Boehringer Ingelheim. Praxbind (idarucizumab) injection, for intravenous use, prescribing information, http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Praxbind/Praxbind.pdf; Accessed 11.11.15.
61. 61 Pollack, C.V., Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
62. 62 Fukuda, T., Honda, Y., Kamisato, C., et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 107 (2012), 253–259.
63. 63 Halim, A.B., Samama, M.M., Mendell, J., Ex vivo reversal of the anticoagulant effects of edoxaban. Thromb Res 134 (2014), 909–913.
64. 64 Wang, X., Mondal, S., Wang, J., et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 14 (2014), 147–154.
65. 65 Escolar, G., Fernandez-Gallego, V., Rellano-Rodrigo, E., et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One, 8, 2013, e78696.
66. 66 Lu, G., Deguzman, F.R., Hollenbach, S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19 (2013), 446–451.
67. 67 Siegal, D.M., Curnutte, J.T., Connolly, S.J., et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 373 (2015), 2413–2424.
68. 68 Bakhru, S., Laulicht, B., Jiang, X., et al. A synthetic small molecule antidote for anticoagulants [abstract]. Eur Heart J 34:suppl (2013), 188–189.
69. 69 Laulicht, B., Bakhru, S., Jiang, X., et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 [abstract]. J Thromb Haemost, 11(suppl 2), 2013, 1322.
70. 70 Ansell, J.E., Bakhru, S.H., Laulicht, B.E., et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371 (2014), 2141–2142.
71. 71 Majeed, A., Hwang, H.G., Connolly, S.J., et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128 (2013), 2325–2332.
72. 72 van der, Hulle T., Kooiman, J., den Exter, P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12 (2014), 320–328.
73. 73 Healey, J.S., Eikelboom, J., Douketis, J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126 (2012), 343–348.
74. 74 Larsen, T.B., Rasmussen, L.H., Skjoth, F., et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61 (2013), 2264–2273.
75. 75 Zalesak, M., Siu, K., Francis, K., et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 6 (2013), 567–574.